

NOTIFICATION OF ATTENDANCE AND FORM FOR ADVANCE VOTING

by postal voting in accordance with Section 22 of the Act (2020:198) on temporary exceptions to facilitate the execution of general meetings in companies and other associations

Submitted to Hansa Biopharma AB (publ) no later than May 11, 2021.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Hansa Biopharma AB (publ), Reg. No. 556734-5359 at the Annual General Meeting on May 12, 2021. The voting right is exercised in accordance with the below marked voting options.

Name of the shareholder	Personal identity number/registration number
Telephone number	E-mail

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions

Assurance (if the undersigned represents the shareholder by proxy): I, the undersigned, solemnly declare that the enclosed power of attorney corresponds to the original and that it has not been revoked

Place and date
Signature
Clarification of signature

Instructions to vote in advance:

- Complete the shareholder information above
- Select the preferred voting options below
- Print, sign and send the form in original to Advokatfirman Vinge KB, Att: Anders Sundin Lundberg, Box 1703, 111 87 Stockholm, Sweden. A completed and signed form may also be submitted electronically and shall, in that case, be sent to hansabiopharma@vinge.se.

- If the shareholder votes in advance by proxy, a power of attorney shall be enclosed to the form. If the shareholder is a legal entity, a certificate of incorporation or a corresponding document shall be enclosed to the form
- Please note that a shareholder whose shares have been registered in the name of a bank or securities institute must re-register its shares in its own name to vote. Instructions for this is included in the notice convening the meeting

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented. One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by the company will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

The form, together with any enclosed authorisation documentation, shall be provided to Hansa Biopharma no later than May 11, 2021. An advance vote can be withdrawn up to and including May 11, 2021 by contacting hansabiopharma@vinge.se.

For complete proposals for the items on the agenda, kindly refer to the notice convening the meeting and the proposals on Hansa Biopharma's webpage.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual General Meeting in Hansa Biopharma on May 12, 2021

The options below comprise the proposals submitted by the Board of Directors and the Nomination Committee which are included in the notice convening the Annual General Meeting.

1. Election of chairman of the meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
2. Election of one or two persons to attest the minutes. Jannis Kitsakis (AP4) Yes <input type="checkbox"/> No <input type="checkbox"/>
3. Preparation and approval of the voting list Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Determination as to whether the meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
7(a) Resolution regarding the adoption of the income statement and the balance sheet, and of the consolidated income statement and the consolidated balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
7(b) Resolution regarding allocation of the company's result according to the adopted balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
7(c) Resolution regarding discharge from liability for the members of the Board of Directors and the CEO
7(c)(i) Ulf Wiinberg, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
7(c)(ii) Birgit Stattin Norinder, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
7(c)(iii) Anders Gersel Pedersen, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
7(c)(iv) Andreas Eggert, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
7(c)(v) Eva Nilsagård, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
7(c)(vi) Mats Blom, member of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>

<p>7(c)(vii) Søren Tulstrup, CEO</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>8(a) Determination of the number of members of the Board of Directors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>8(b) Determination of the number of auditors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>9(a) Determination of fees for members of the Board of Directors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>9(b) Determination of fees for auditors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>10. Election of the members of the Board of Directors</p>
<p>10(a) Ulf Wiinberg</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>10(b) Anders Gersel Pedersen</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>10(c) Andreas Eggert</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>10(d) Eva Nilsagård</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>10(e) Hilary Malone</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>10(f) Mats Blom</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>11. Election of the chairman of the Board of Directors Ulf Wiinberg</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12. Election of auditors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>13. Proposal regarding principles for appointing the Nomination Committee</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14. Presentation of the Board of Directors' remuneration report for approval</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>15. Proposal regarding guidelines for executive remuneration</p>

Yes <input type="checkbox"/> No <input type="checkbox"/>
16. Proposal regarding the amendment of the articles of association Yes <input type="checkbox"/> No <input type="checkbox"/>
17. Proposal to adopt a long-term incentive program based on performance-based share rights for employees at Hansa Biopharma
17(a). Proposal to adopt the Share Rights Program 2021 Yes <input type="checkbox"/> No <input type="checkbox"/>
17(b). Resolution on the transfer of own ordinary shares to participants in Share Rights Program 2021 and in Share Rights Programs 2018-2020 and the market Yes <input type="checkbox"/> No <input type="checkbox"/>
17(c). Resolution on equity swap arrangements with third parties Yes <input type="checkbox"/> No <input type="checkbox"/>
18. Proposal to adopt a long-term incentive program based on employee stock options for employees at Hansa Biopharma
18(a). Proposal regarding the adoption of Option Program 2021 Yes <input type="checkbox"/> No <input type="checkbox"/>
18(b). Proposal regarding authorization for the Board of Directors to issue new class C shares, authorization to repurchase issued class C shares, transfer own ordinary shares to participants in the programs and the market Yes <input type="checkbox"/> No <input type="checkbox"/>
18(c). Resolution on equity swap arrangements with third parties Yes <input type="checkbox"/> No <input type="checkbox"/>
19. Proposal to resolve on an amendment of the terms of the long-term incentive program based on employee stock options adopted in 2019 and 2020
19(a). Proposal to resolve on an amendment of the terms of the long-term incentive program based on employee stock options adopted in 2019 as well as transfer of warrants under the amended terms Yes <input type="checkbox"/> No <input type="checkbox"/>
19(b). Proposal to resolve on an amendment of the terms of the long-term incentive program based on employee stock options adopted in 2020 Yes <input type="checkbox"/> No <input type="checkbox"/>
20. Proposal regarding resolution on authorization for the Board of Directors to resolve on new issue of ordinary shares and warrants and/or convertibles
20(a). Main proposal Yes <input type="checkbox"/> No <input type="checkbox"/>
20(b). Alternative proposal Yes <input type="checkbox"/> No <input type="checkbox"/>

The shareholder wishes that the resolutions under one or several items in the form above be deferred to a continued general meeting

(Completed only if the shareholder has such a wish)

Item/items (use numbering):